Financial Ratios

VENUS REMEDIES LTD.

NSE : VENUSREMBSE : 526953ISIN CODE : INE411B01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE329.00-5.7 (-1.7 %)
PREV CLOSE ( ) 334.70
OPEN PRICE ( ) 345.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2187
TODAY'S LOW / HIGH ( )324.00 345.00
52 WK LOW / HIGH ( )185.65 429.6
NSE328.70-6.5 (-1.94 %)
PREV CLOSE( ) 335.20
OPEN PRICE ( ) 332.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 328.70 (1134)
VOLUME 38623
TODAY'S LOW / HIGH( ) 323.05 342.95
52 WK LOW / HIGH ( )188.6 430
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)21.6736.6543.97-6.67-21.97
   CEPS(Rs)45.1461.0271.7518.494.73
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)357.63336.21313.10269.21276.25
   Tax Rate(%)28.18-9.66-32.18-31.364.07
Margin Ratios
   Core EBITDA Margin(%)11.4411.939.1113.4511.36
   EBIT Margin(%)7.507.7510.452.12-1.03
   Pre Tax Margin(%)7.507.757.98-1.96-9.36
   PAT Margin (%)5.398.4910.55-2.57-8.98
   Cash Profit Margin (%)11.2214.1417.217.131.94
Performance Ratios
   ROA(%)4.888.719.11-1.20-3.66
   ROE(%)6.2511.7215.10-2.44-7.65
   ROCE(%)8.039.5510.801.15-0.48
   Asset Turnover(x)0.911.030.860.470.41
   Sales/Fixed Asset(x)0.940.990.880.510.45
   Working Capital/Sales(x)2.193.174.094.71-347.18
Efficiency Ratios
   Fixed Capital/Sales(x)1.071.011.141.972.22
   Receivable days39.1514.8316.3934.8645.68
   Inventory Days81.2077.6390.83158.08167.43
   Payable days53.2057.0455.4669.5460.84
Valuation Parameters
   PER(x)7.477.346.240.000.00
   PCE(x)3.594.413.831.227.00
   Price/Book(x)0.450.800.880.080.12
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)0.380.600.690.761.11
   EV/Core EBITDA(x)2.834.515.515.208.60
   EV/EBIT(x)5.027.796.6235.78-107.09
   EV/CE(x)0.330.600.650.380.46
   M Cap / Sales0.400.620.660.090.14
Growth Ratio
   Net Sales Growth(%)-6.7712.0760.706.09-14.99
   Core EBITDA Growth(%)-7.1919.5438.5420.23-13.30
   EBIT Growth(%)-9.72-16.95693.00317.69-125.92
   PAT Growth(%)-40.87-9.74759.6969.65-1.99
   EPS Growth(%)-40.87-16.66759.6969.65-1.99
Financial Stability Ratios
   Total Debt/Equity(x)0.080.090.120.650.86
   Current Ratio(x)4.383.202.431.311.00
   Quick Ratio(x)2.821.681.070.680.44
   Interest Cover(x)4.230.52-0.12
   Total Debt/Mcap(x)0.180.110.147.797.19

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.